Key Takeaways
- Strong quarter, broad-based growth: Revenue grew ~17% YoY and EBITDA expanded ~40% YoY, driven by market share gains, new product launches, and easing input costs.
- Teva integration on track, revenue ramp ahead: The acquired facility passed a German health authority audit with no major observations, but its full revenue potential is only expected from April 2024 onwards.
- Margin tailwind from raw materials is fading: Management confirmed most of the benefit from lower raw material costs is done; future margin improvement must come from operating leverage and product mix.
- Capital allocation remains undefined: Free cash flow was negative this quarter due to planned capex, and a decision on splitting future free cash flow between a buyback or dividends is still pending.
- What to watch next quarter: The pace of revenue contribution from the Teva facility, progress on backward integration DMF filings, and any concrete M&A or capital allocation announcements.
Teva Facility Integration & Capacity Expansion
- Audit clearance achieved: A recent audit by German health authorities was completed successfully with no major observations, a key de-risking event for the integration.
- Revenue ramp is back-end loaded: The company expects revenue contribution to increase quarter-on-quarter, but the "full potential of revenue generation only somewhere in April 24 onwards," as capacity expansion and customer qualifications progress.
- Capacity doubling to meet order book: The existing plant was reaching optimum capacity, and the order book for next year has a "decent amount" earmarked for the new facility, with plans to nearly double supplies into existing geographies.
- Breakeven timeline intact: The Teva plant breakeven target of "first quarter 25" is "definitely" still on track.
- Further investment planned: After the initial ₹200 cr investment, management expects to invest more to increase capacity further "maybe after a year and a half."
Mark Saldanha: "you will see the full potential of revenue generation only somewhere in April 24 onwards"
Margin Dynamics & Cost Structure
- Input cost tailwinds drove the beat: A reduction in rates for a few raw materials and lower freight rates compared to last year were the primary drivers of the ~40% YoY EBITDA expansion.
- The easy gains are over: Management confirmed it is "fair enough to say" that most of the tailwind from raw material cost reductions is done, and future benefits will come from operating leverage and product portfolio evolution.
- Price erosion is present but manageable: The company is not immune to US price erosion, but the impact was "not dramatic" and less severe than what is seen in the prescription segment. Management found it "difficult to quantify exactly."
- UK tax rate headwind: The increase in the UK corporate tax rate from 19% to 25% created a drag during the quarter.
- Depreciation stepped up: The increase in depreciation this quarter includes the Teva facility, which started contributing to the charge from this quarter onwards.
Backward Integration Strategy
- Objective is supply security, not just cost: The primary rationale for backward integration is to strengthen sourcing capabilities and ensure reliability on key molecules, preventing situations where "manufacturers tend to exploit the situation" during market tightness.
- Phased, molecule-by-molecule approach: The company has selected one item in each therapeutic category (ibuprofen in pain, one in anti-allergy, one in digestive) and plans to expand the portfolio after establishing a foothold.
- Benefits are a CY24 event: The impact of backward integration on lowering raw material costs is expected in the "mid or latter part of 2024" (calendar year).
- DMF filing still in progress: The company is "still working towards filing DMFs" and is optimistic about filing by "the end of this financial year."
Mark Saldanha: "that was the objective more than anything else that because when prices go up or when circumstances happen in the market manufacturers tend to exploit the situation, so we that's the reason why we wanted to backward integrate ourselves."
Market Position & Competitive Dynamics
- Growth is share-taking and new launches: Revenue expansion is attributed to market share gains from competitors like Perrigo and PLDS, combined with new product additions to the portfolio.
- US and Europe both strong: Management is optimistic on both markets and believes the growth trend will continue for the coming year. The US revenue mix is expected to be "very close to 48% maybe and between 45% to 48% by FY25," with the UK around 40-45%.
- Geopolitical immunity assumed: Management believes the pharma industry is "quite immune" to geopolitical scenarios because "people still need medications" and expects to be the "least impacted."
- The market remains tough: When asked about the competitive environment in UK and US OTC markets, management characterized it as "crowded and tough as always that's the nature of the beast."
Mark Saldanha: "Well, it's crowded and tough as always that's the nature of the beast"
Product Pipeline & R&D
- Recent approvals secured: Key product approvals were received from the USFDA and market authorizations from the UK MHRA in the pain, cough and cold, and digestive segments, including Esomeprazole and Cyanocobalamin.
- Filing cadence set: The company is targeting 4-5 ANDAs per year in the US and 15-20 market authorizations per year in Europe, with 60-70 products currently in the works.
- R&D spend to rise gradually: R&D spend is expected to be about 2% of revenue for FY25-26, with the increase for ANDA filings described as "a gradual increase, but it will be an increase for sure."
- OTC/RX mix stable: The future OTC/RX mix is expected to remain "pretty much standard maybe 5% here and there OTC maybe 75 RX maybe 25" over the next 3-5 years.
Capital Allocation & Strategic Optionality
- Near-term cash flow is constrained: Free cash flow was negative ₹29.3 crores this quarter due to higher capex, which is in line with the plan for scaling the acquired Teva unit.
- Shareholder returns are under review: Management will split future free cash flow between a potential buyback or dividends, but no decision or timeline has been committed for FY24.
- M&A exploration is active: The company is planning M&A in a couple of geographies, with Europe being one target. Management confirmed they are "in dialogue but nothing concrete."
- Branded business is a long-term option: While branded business offers "definitely lucrative bottom lines," it requires significant upfront marketing and sales investment. The company may explore brands in India and certain European markets, with M&A as a potential entry path.
Mark Saldanha: "The branded business does give definitely lucrative bottom lines, but that is once it reaches a certain level of revenue and optimization till then you have to invest a lot of money into marketing and sales and everything. So, it's like a chicken and egg situation."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Teva facility full revenue potential | Full potential of revenue generation from acquired unit | April 2024 onwards |
| Teva plant breakeven | Plant reaches breakeven | First quarter FY25 |
| US revenue mix | US at 45-48% of total revenue | By FY25 |
| Backward integration raw material benefit | Lower raw material costs from backward integration | Mid to latter part of CY2024 |
| DMF filing for backward integration | File DMFs for backward-integrated products | By end of current financial year |
| US ANDA filing cadence | 4-5 ANDAs per year | Ongoing annual target |
| Europe/UK filing cadence | 15-20 market authorizations per year | Ongoing annual target |
| R&D spend | Approximately 2% of revenue, may go slightly higher | FY25-26 |
| Further Teva capacity investment | Additional investment to expand capacity | "Maybe after a year and a half" |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Operating revenue | ₹531 cr, +17.4% YoY vs ₹452 cr |
| US & North America revenue | ₹222.3 cr, +16.8% YoY |
| UK & EU revenue | ₹48.4 cr, +10.3% YoY |
| Rest of World revenue | ₹27.3 cr |
| Gross margin | 52.4%, +174 bps YoY from 50.7% |
| EBITDA | ₹113.9 cr, +41.9% YoY and +11.7% QoQ |
| EBITDA margin | 21.4% |
| Profit after tax | ₹83.9 cr, +39.5% YoY vs ₹60.1 cr |
| EPS | ₹1.84 |
| H1 FY24 operating revenue | ₹1,031.3 cr, +16.4% YoY vs ₹886 cr |
| H1 FY24 EBITDA margin | 20.9% |
| H1 FY24 PAT | ₹154.3 cr, +28.3% YoY vs ₹120.3 cr |
| H1 FY24 CAPEX | ₹119.9 cr, includes Teva facility acquisition payment |
| H1 FY24 free cash flow | -₹29.3 cr, driven by higher CAPEX |
| Cash on books | ₹661 cr as of 30th September 2023, debt-free |
| R&D spend | 1.6% of sales in H1 FY24; FY25-26 guidance of ~2% |
| OTC vs RX mix (global) | 70:30; US OTC ~78% |
| US ANDA filing target | 4–5 per year |
| Europe/UK market authorization target | 15–20 per year |
| Teva facility quarterly expense | ~₹10 cr |
| Backward integration molecules revenue share | ~30% of total revenue |
| Planned additional CAPEX (next 6–12 months) | ₹80–100 cr |
| Total planned Teva facility CAPEX including acquisition | ~₹200 cr |